Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Mar 1;62(5):608-9.
doi: 10.1093/cid/civ1007. Epub 2015 Dec 13.

Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials

Joseph G Toerner  1 , Edward Cox  1
Affiliations
Editorial

Editorial Commentary: A Collaborative Model for Endpoint Development: Advancing the Science of Antibacterial Drug Clinical Trials

Joseph G Toerner et al. Clin Infect Dis. .
No abstract available

Keywords: antibacterial drug development; clinical endpoints; non-inferiority trial design.

PubMed Disclaimer

Comment on

References

    1. Drusano G. Early endpoints for acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:2221–2. - PMC - PubMed
    1. Itani KM, Shorr AF. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials. Clin Infect Dis 2014; 58(suppl 1):S4–9. - PubMed
    1. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169–79. - PubMed
    1. Corey RG, Good S, Jiang H et al. . Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis 2015; 60:254–62. - PubMed
    1. Shorr AF, Lodise TP, Corey RG et al. . Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2015; 59:864–71. - PMC - PubMed

Substances